Medical Crossfire

Welcome to Medical Crossfire

Medical Crossfire is a national health care education program dedicated to improving medical practices and patient care through discussion, debate, and authoritative peer exchange on important clinical issues. Produced by Healthcare First, Medical Crossfire is based on the belief that exposure to differing—and often controversial—opinions, insights, and philosophies fuels learning and understanding among health care professionals.

We strive to surpass the value of traditional educational methods by providing validation, relevance, and practicality through exchange between leading experts.

Metabolex Announces Positive Results From Phase 2 Clinical Trial Of MBX-8025

Wed, 19 Nov 2008 00:00:00 PST

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008. MBX-8025 is an oral drug candidate that is being evaluated for the treatment of dyslipidemia.

XTL Biopharmaceuticals Announces Top-Line Results From The Bicifadine Phase 2b Study For Diabetic Neuropathic Pain

Wed, 19 Nov 2008 00:00:00 PST

XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial's primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in pain score during the course of treatment.

Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir Vs. Lopinavir/ritonavir As Part Of HIV Combination Therapy In Treatment-Experienced Adults

Wed, 19 Nov 2008 00:00:00 PST

Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naive, treatment-experienced HIV-1 infected adults. A 96-week resistance analysis from the study, known as TITAN, was presented in an oral presentation at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, UK on November 13, 2008.

More News...

High-risk patients with stage 2 HTN (Systolic BP= 160 or higher or Diastolic BP= 100 or higher), evidence-based first line pharmacotherapy is recommended as: ( surveys)